Abstract: The object of the present invention is a pharmaceutical composition, which comprises, as active principle, a combination of an adenosinergic agonist and a compound selected from the opiates, benzodiazepines and NMDA antagonists.

Abstract: The present invention relates to compounds of the formula: ##STR1## and their use in therapeutics, especially as medicaments with anti-inflammatory and analgesic properties.

Abstract: The present invention relates to the carbocyclic diarylmethylene derivatives of formula (I): ##STR1## and to their use in therapeutics, especially as drugs with anti-inflammatory and analgesic properties.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as drugs having antiproliferative properties and affording an effective treatment for diseases such as cancer, psoriasis, atherosclerosis, restenosis phenomena or any other pathological condition due to cell proliferation.

Abstract: The present invention relates to a novel pharmaceutical composition for the preparation of effervescent powders or tablets incorporating ibuprofen or one of its pharmaceutically acceptable salts as the active ingredient.This composition comprises:an effective amount of ibuprofen or one of its pharmaceutically acceptable salts;a pharmaceutically acceptable effervescent system comprising at least one alkaline carbonate and at least one organic acid, preferably in a sufficient amount to give a pH below about 8; andat least one pharmaceutically acceptable antioxidant in a sufficient amount to stabilize the ibuprofen.This composition has a remarkable stability both in powder form and in tablet form.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as analgesics and as antihypertensives.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics as analgesics, as antihypertensives and as drugs with antiproliferative properties.

Abstract: A novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredients. The acetylsalicylic acid is in the form of a water soluble salt or complex and is in association with metoclopramide or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable hydrophilic polymer in an amount sufficient to stabilize the metoclopramide. This composition has remarkable stability in powder form and can be used to prepare sachets for the treatment of migraine.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as drugs with analgesic properties.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their tautomeric forms, as well as their addition salts, and to their use in therapeutics, especially for the treatment and prevention of cardiovascular diseases and in particular for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall, especially atherosclerosis.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their tautomeric forms, as well as their addition salts, and to their use in therapeutics, especially for the treatment and prevention of cardiovascular diseases and in particular for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall, especially atherosclerosis.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as drugs having antiproliferative properties and affording an effective treatment for diseases such as atherosclerosis, restenosis phenomena or any other pathological condition due to cell proliferation.

Abstract: The present invention relates to the derivatives of formula: ##STR1## and to their tautomeric forms as well as to their addition salts and to their use in therapy, in particular for the treatment of cardiovascular diseases, especially for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their tautomeric forms, as well as their addition salts, and to their use in therapeutics, especially for the treatment of cardiovascular diseases and in particular for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall.

Abstract: The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially in the central nervous system as analgesics, anticonvulsants, antiepileptics, anxiolytics, antidepressants and neuroprotectors, and in the cardiovascular system as antiarrhythmics, antihypertensives and platelet aggregation inhibitors.

Abstract: The present invention relates to the derivatives of formula: ##STR1## as well as to their addition salts and to their use in therapy, in particular for the treatment of cardiovascular diseases, especially for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall.

Abstract: The present invention relates to the derivatives of the formula ##STR1## in the (S) configuration, to their addition salts and to their use in therapy, especially as drugs with analgesic properties.

Abstract: The present invention relates to the derivatives of formula (I): ##STR1## and their addition salts, and to their use in therapeutics, especially for the treatment of cardiovascular diseases and in particular for the treatment of hypertension and cardiac insufficiency.

Abstract: The invention relates to novel monoesters and diesters of 9,10-endoethano-9,10-dihydroanthracene-11,11-dicarboxylic acid.These novel monoesters and diesters correspond to the following structural chemical formula (II): ##STR1## in which R.sup.1 and R.sup.2 are identical or different and can represent H, an alkali metal or alkaline earth metal atom, a linear or branched alkyl group having from 1 to 6 carbon atoms, an alicyclic group having form 3 to 6 carbon atoms, an alkenyl group having from 2 to 6 carbon atoms, defined in their cis or trans variety, or an alkynyl group having from 2 to 6 carbon atoms, the said groups optionally being substituted by one or more functional groups such as ether, epoxide, halogeno, cyano, ester, aldehyde, ketone, aryl etc., where R.sup.1 and R.sup.2 cannot be H or ethyl simultaneously. These addition products constitute valuable intermediates for the preparation of methylidenemalonates in high yields and with a high purity.

Abstract: The present invention relates to the derivatives of the formula ##STR1## where the substituents are defined in the specification. These compounds possess thromboxane receptor antagonist properties.